Spectranetics Announces Launch of AngioScore's 200-mm AngioSculpt PTA Scoring Balloon Catheters

July 9, 2014—The Spectranetics Corporation announced that its wholly owned subsidiary, AngioScore, Inc., launched the new 200-mm-length AngioSculpt percutaneous transluminal angioplasty (PTA) scoring balloon catheters for the treatment of above-the-knee peripheral artery disease. AngioScore was acquired by Spectranetics in June 2014.

According to the company, the catheters incorporate 200-mm balloons in diameters of 4, 5, and 6 mm with a scoring element specifically designed for these longer balloons. The devices are expected to be particularly useful in treating the typical complex and long lesions found above the knee.

The new AngioSculpt catheters received US Food and Drug Administration (FDA) 510(k) clearance to be marketed for the dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. They are not approved for use in the coronary vasculature or neurovasculature, advised the company.

In Spectranetics’ press release, Nelson L. Bernardo, MD, commented, “These new longer scoring balloons extend the capability of the AngioSculpt in treating the most challenging femoropopliteal lesions safely and efficiently and will be a very important addition to the armamentarium of physicians treating complex endovascular disease.” Dr. Bernardo is Medical Director of the Peripheral Vascular Laboratory, MedStar Heart Institute at MedStar Washington Hospital Center in Washington, DC.